JL
Therapeutic Areas
Rhythm Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| IMCIVREE® (setmelanotide) | Acquired Hypothalamic Obesity | Phase 3 / Approved |
| Bivamelagon (LB54640) | Acquired Hypothalamic Obesity | Phase 2 |
| RM-718 | Not Specified (Weekly MC4R agonist) | Phase 1 |
Leadership Team at Rhythm Pharmaceuticals
DM
David Meeker, M.D.
Chair, President and Chief Executive Officer
HS
Hunter Smith
Chief Financial Officer